Novocure

Historical price data

Novocure is a commercial-stage oncology company with a mission to extend survival in aggressive cancers through its innovative Tumor Treating Fields (TTFields) therapy. Its core achievement is the successful development and regulatory approval of TTFields for glioblastoma and, more recently, locally advanced pancreatic cancer, validating its unique physics-based mechanism. The company's strategy is to methodically expand TTFields into large, underserved solid tumor indications through a focused clinical pipeline while leveraging its commercial infrastructure and deep scientific expertise.

Tumor Treating Fields (TTFields): Low-intensity, alternating electric fields delivered non-invasively via wearable devices to disrupt cancer cell division.

Novocure has no direct competitors with an approved electric field modality, enjoying a strong patent moat. It competes contextually with standard chemotherapies, radiation, and emerging immunotherapies across its target indications, differentiating via its unique mechanism and combinability.